Literature DB >> 1349833

Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus.

E E Krieckhaus1, J W Donahoe, M A Morgan.   

Abstract

Explicit consolidation of memory, or fixation of declarative belief, appears to be physically represented in changes of synaptic conductances of neurons in the parietal-temporal-occipital association cortex (PTO) of the mammalian forebrain. This fixation of belief in PTO is postulated to be critically dependent on a diffuse reinforcement signal via the inferior temporal cortex (ITC) ultimately caused by an increased output of the CA1 pyramidal cells of hippocampus. Analogous to the reinforcing mechanisms of other forebrain systems, this updating of the connection weights of the neural nets in PTO by the output of the critical neurons in CA1 is directly related to concentrations of dopamine (DA). We propose that the delusions (i.e., unreasonable beliefs) of paranoid schizophrenia are caused by a hyperactivity of the same DA-sensitive CA1 neurons that are responsible for the fixation of normal beliefs. The dramatic reduction in delusions with administration of neuroleptics, as DA D2 blockers, in schizophrenics may thus be explained by their acting to ameliorate the hyperactivity of these CA1 DA D2 receptors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349833     DOI: 10.1016/0006-3223(92)90242-r

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Hippocampal pyramidal cell disarray correlates negatively to cell number: implications for the pathogenesis of schizophrenia.

Authors:  S A Jönsson; A Luts; N Guldberg-Kjaer; A Brun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

2.  MRI abnormalities of the hippocampus and cavum septi pellucidi in females with schizotypal personality disorder.

Authors:  Chandlee C Dickey; Robert W McCarley; Mina L Xu; Larry J Seidman; Martina M Voglmaier; Margaret A Niznikiewicz; Erin Connor; Martha E Shenton
Journal:  Schizophr Res       Date:  2006-10-05       Impact factor: 4.939

Review 3.  A selectionist approach to reinforcement.

Authors:  J W Donahoe; J E Burgos; D C Palmer
Journal:  J Exp Anal Behav       Date:  1993-07       Impact factor: 2.468

Review 4.  GABAergic mechanisms of hippocampal hyperactivity in schizophrenia.

Authors:  Stephan Heckers; Christine Konradi
Journal:  Schizophr Res       Date:  2014-10-18       Impact factor: 4.939

Review 5.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

7.  Jumping to conclusions: a network model predicts schizophrenic patients' performance on a probabilistic reasoning task.

Authors:  Simon C Moore; Joselyn L Sellen
Journal:  Cogn Affect Behav Neurosci       Date:  2006-12       Impact factor: 3.282

8.  Dexamethasone target sites in the central nervous system and their potential relevance to mental illness.

Authors:  M K Birmingham; M Sar; W E Stumpf
Journal:  Cell Mol Neurobiol       Date:  1993-08       Impact factor: 5.046

9.  Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features.

Authors:  Sarah E Bergen; Ayman H Fanous; Dermot Walsh; F Anthony O'Neill; Kenneth S Kendler
Journal:  Schizophr Res       Date:  2009-03-05       Impact factor: 4.939

10.  Amplitude of low-frequency oscillations in schizophrenia: a resting state fMRI study.

Authors:  Matthew J Hoptman; Xi-Nian Zuo; Pamela D Butler; Daniel C Javitt; Debra D'Angelo; Cristina J Mauro; Michael P Milham
Journal:  Schizophr Res       Date:  2009-10-24       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.